BCR and leukemia: Collectively, these observations are consistent with reduced disease latency and more aggressive leukemia in Gadd45a−/−/BCR-ABL mice, pointing to a potent and novel tumor suppressor role for Gadd45a in BCR/ABL driven leukemogenesis.